Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study in Metastatic Melanoma Using a Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 TCR-Gene Engineered Lymphocytes and Subsequent Peptide Immunization

NCT00091104 is registered in ClinicalTrials.gov with National Institutes of Health Clinical Center (CC) as lead sponsor.

NCT NCT00091104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00091104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study in Metastatic Melanoma Using a Lymphodepleting Conditioning Followed by Infusion of Anti-MART-1 TCR-Gene Engineered Lymphocytes and Subsequent Peptide Immunization
Lead sponsor
National Institutes of Health Clinical Center (CC)
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2004
Completion date
October 31, 2010
Enrollment
136 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma (skin)